公开(公告)号：US20230293659A1

公开(公告)日：2023-09-21

申请号：US18006627

申请日：2021-07-30

Applicant: GlaxoSmithKline Biologicals SA

Inventor： Cindy CASTADO ,  Sandra GIANNINI

IPC: A61K39/114 ,  A61P37/04

CPC classification number: A61K39/114 ,  A61P37/04 ,  A61K2039/53

Abstract: The application discloses a truncated Fusobacterium nucleatum Fusobacterium adhesin A (FadA) protein wherein at least a signal peptide which is at least 80%, 85%, 90% or 95% identical to SEQ ID NO:8 is deleted from the N-terminus of the FadA protein. Polynucleotides and vectors encoding the truncated FadA protein and bacteriophage comprising a gene encoding FadA as well of methods of treating or preventing disease such as colorectal cancer or periodontitis are also disclosed in the application.

公开(公告)号：US11744890B2

公开(公告)日：2023-09-05

申请号：US16768416

申请日：2018-11-30

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Ahmad Taimour Baig ,  Juan Jose Diaz Garcia ,  Chad Austin Farrenburg ,  Kent Raymond Myers ,  Jeri Kay Sandvick ,  Jeb Yeatts Vandenburg

IPC: A61K36/00 ,  A61K39/39 ,  A61K36/185 ,  A61K39/00

CPC classification number: A61K39/39 ,  A61K36/185 ,  A61K2039/55577 ,  A61K2236/331

Abstract: Crude aqueous extracts of Quillaja saponaria Molina containing at least the QS-21 main peak and 2018 component, wherein the ratio of 2018 component/QS-21 main peak is ≤0.075, as measured by UV absorbance at 214 nm, methods for obtaining such extracts and related aspects.

公开(公告)号：US20230272000A1

公开(公告)日：2023-08-31

申请号：US18098949

申请日：2023-01-19

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Ahmad Taimour BAIG ,  Felicie Georgette, Colette DENET ,  Juan Jose DIAZ GARCIA ,  Chad Austin FARRENBURG ,  Lora Lea LAWRENCE ,  Kent Raymond MYERS ,  Jeri Kay SANDVICK ,  Jeb Yeatts VANDENBURG

IPC: C07J63/00 ,  A61K39/12 ,  A61K39/25 ,  A61K39/39 ,  C12N7/00

CPC classification number: C07J63/008 ,  A61K39/12 ,  A61K39/25 ,  A61K39/39 ,  C12N7/00 ,  A61K2039/55555

Abstract: Saponin extracts containing at least 93% QS-21 main peak and 0.25-3% 2018 component by UV absorbance at 214 nm, methods for making said extracts, their use as vaccine adjuvants and related aspects.

公开(公告)号：US11723966B2

公开(公告)日：2023-08-15

申请号：US16638595

申请日：2018-08-13

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Ashwani Kumar Arora ,  Vincent Weynants

IPC: A61K39/00 ,  A61K39/102 ,  A61P31/04 ,  A61K39/104

CPC classification number: A61K39/102 ,  A61K39/1045 ,  A61P31/04 ,  A61K2039/545 ,  A61K2039/55555

Abstract: The present invention relates to immunogenic compositions, such as vaccines, comprising immunogenic polypeptides from Haemophilus influenzae and Moraxella catarrhalis, for use in methods of boosting an immune response and methods of treatment using same. More particularly, the invention relates to use of such immunogenic compositions in methods of treating or preventing exacerbation of chronic obstructive pulmonary disease.

公开(公告)号：US11707513B2

公开(公告)日：2023-07-25

申请号：US15319665

申请日：2015-07-16

Applicant: GLAXOSMITHKLINE BIOLOGICALS, SA

Inventor： Alessia Biolchi ,  Brunella Brunelli ,  Marzia Monica Giuliani ,  Vega Masignani

IPC: A61K39/095 ,  C07K14/22 ,  A61K39/00 ,  A61K39/385

CPC classification number: A61K39/095 ,  A61K39/385 ,  C07K14/22 ,  A61K39/00 ,  A61K2039/545 ,  A61K2039/55505 ,  A61K2039/70 ,  C07K2319/00

Abstract: Meningococcal vaccines can be improved by including multiple alleles or variants of fHbp, in order to provide broader coverage of the diversity which is known for this protein, and/or by reducing the quantity of an OMV component in each dose.

公开(公告)号：US11701422B2

公开(公告)日：2023-07-18

申请号：US16800384

申请日：2020-02-25

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Alessandra Vitelli ,  Alfredo Nicosia ,  Riccardo Cortese

IPC: A61K39/155 ,  A61K39/145 ,  A61K39/12 ,  C07K14/005 ,  C12N15/85 ,  C12N15/86 ,  A61K39/00

CPC classification number: A61K39/145 ,  A61K39/12 ,  A61K39/155 ,  C07K14/005 ,  C12N15/85 ,  C12N15/86 ,  A61K2039/53 ,  C12N2710/10343 ,  C12N2760/18522 ,  C12N2760/18534 ,  C12N2800/22 ,  C12N2840/20

Abstract: The invention relates to an expression system comprising polynucleotides encoding proteins, wherein the expression system comprises a first polynucleotide encoding at least one protein, peptide or variant thereof, which induces a T cell response, and a second polynucleotide encoding at least one protein, peptide or variant thereof, which induces an anti-pathogenic B cell response. The invention further relates to protein mixtures encoded by the expression system and cells comprising the expression system or the protein mixture and pharmaceutical compositions comprising the expression system or the protein mixture.

公开(公告)号：US11696923B2

公开(公告)日：2023-07-11

申请号：US18080075

申请日：2022-12-13

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Andrew Geall ,  Katrin Ramsauer ,  Gillis Otten ,  Christian Walter Mandl

IPC: A61K39/00 ,  A61K39/12 ,  A61K31/7088

CPC classification number: A61K31/7088 ,  A61K39/00 ,  A61K39/12 ,  A61K2039/53 ,  A61K2039/55555 ,  C12N2760/18522 ,  C12N2760/18534 ,  C12N2770/36143

Abstract: RNA encoding an immunogen is co-delivered to non-immune cells as the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered RNA lead to two different effects, which interact to produce a strong immune response against the immunogen. The non-immune cells translate the RNA and express the immunogen. Infiltrating immune cells respond to the RNA by expressing type I interferons and pro-inflammatory cytokines which produce a local adjuvant effect which acts on the immunogen-expressing non-immune cells to upregulate major histocompatibility complex expression, thereby increasing presentation of the translated protein to T cells. The effects on the immune and non-immune cells can be achieved by a single delivery of a single RNA e.g., by a single injection.

公开(公告)号：US20230210975A1

公开(公告)日：2023-07-06

申请号：US18008777

申请日：2021-06-11

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Roberto ADAMO ,  Filippo CARBONI ,  Roberta COZZI ,  Immaculada MARGARIT Y ROS ,  Maria Rosaria ROMANO

IPC: A61K39/09 ,  A61P31/04

CPC classification number: A61K39/092 ,  A61P31/04 ,  A61K2039/6031

Abstract: Methods of inducing an immunogenic response against a bacterial polysaccharide or oligosaccharide, and constructs and compositions for use in such methods.

公开(公告)号：US20230158134A1

公开(公告)日：2023-05-25

申请号：US18075064

申请日：2022-12-05

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Virginia AMMENDOLA ,  Stefano COLLOCA ,  Alessandra VITELLI ,  Benjamin WIZEL

IPC: A61K39/12 ,  A61K39/205 ,  C07K14/005 ,  C12N15/86 ,  A61K39/235 ,  C12N7/00

CPC classification number: A61K39/12 ,  A61K39/205 ,  C07K14/005 ,  C12N15/86 ,  A61K39/235 ,  C12N7/00 ,  A61P31/14

Abstract: The invention provides adenoviral vectors comprising transgenes encoding Lyssaviral antigens. The vectors can be used to produce vaccines for the prophylaxis, amelioration and treatment of diseases caused by Lyssaviral diseases, e.g., rabies.

公开(公告)号：US11655284B2

公开(公告)日：2023-05-23

申请号：US17848205

申请日：2022-06-23

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Kurt Swanson ,  Philip R. Dormitzer

IPC: C07K16/10 ,  A61K39/155 ,  A61K39/12 ,  C07K14/005 ,  A61K39/00

CPC classification number: C07K16/1027 ,  A61K39/12 ,  A61K39/155 ,  C07K14/005 ,  A61K39/00 ,  A61K2039/5252 ,  A61K2039/5256 ,  A61K2039/5258 ,  A61K2039/53 ,  A61K2039/55505 ,  A61K2039/55555 ,  A61K2039/55561 ,  A61K2039/55566 ,  A61K2039/55572 ,  C07K2317/76 ,  C07K2319/00 ,  C07K2319/21 ,  C07K2319/50 ,  C07K2319/73 ,  C12N2760/18522 ,  C12N2760/18534 ,  C12N2770/36143

Abstract: The present invention relates to immunogenic compositions comprising RSV F protein, methods for preparing compositions that contain RSV F protein ecto-domain polypeptides, and to certain engineered RSV F proteins and nucleic acids that encode the engineered RSV F proteins. Compositions prepared using the methods can contain RSV F protein ecto-domain polypeptides in a predominant or single desired form and conformation. The invention also relates to methods for inducing an immune response to RSV F.